EUCTR2004-002880-26-IT进行中（未招募）不适用
A Phase IV, multi-center, cross-sectional study to evaluate the I50L substitution among subjects experiencing virologic failure on a HAART regimen containing atazanavir ATV
BRISTOL-M.SQUIBB0 个研究点目标入组 5,000 人开始时间: 2006年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 5,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A Phase IV, Multi-center, Cross-sectional study to evaluate the I50L substitution among subjects experiencing virologic failure on a HAART regimen containing atazanavir (ATV)Protocol: version 2.0, 2004-07-14Amendment 1: version 1.0, 2005-01-04Subjects experiencing virologic failure after a HAART regimen containing ATVEUCTR2004-002880-26-DEBristol-Myers Squibb International Corporation5,000
进行中（未招募）
1 期
A Phase IV, Multi-center, Cross-sectional study to evaluate the I50L substitution among subjects experiencing virologic failure on a HAART regimen containing atazanavir (ATV)Protocol: version 2.0, 2004-07-14Amendment 1: version 1.0, 2005-01-04Subjects experiencing virologic failure after a HAART regimen containing ATVEUCTR2004-002880-26-GBBristol-Myers Squibb International Corporation5,000
招募中
4 期
Phase IV study to assess the safety, efficacy and immunogenicity of MJ Pharma-BIOSULIN�® 30:70CTRI/2020/03/024054M J Biopharm Private Limited
Unknown
不适用
Multicentric study to determine the accuracy of a screening tool (Thyvox©) for Primary Hypothyroidism in Adult Patients & to check if there is any association between voice change and Thyroxine Sodium treatmentCTRI/2019/05/019165Abbott India Ltd97
进行中（未招募）
1 期
A Phase 4 study to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged release (SPD503) in Children and Adolescents aged 6 to 17 Years with ADHDEUCTR2018-000821-29-BETakeda Development Center Americas, Inc.288